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ABSTRACT
Background: Intravenous thrombolysis is an effective
emergency treatment for acute ischaemic stroke for
patients meeting specific criteria. Approximately 12% of
eligible patients in England, Wales and Northern Ireland
received thrombolysis in the first quarter of 2013, yet as
many as 15% are eligible to receive treatment.
Suboptimal use of thrombolysis may have been largely
attributable to structural factors; however, with the
widespread implementation of 24/7 hyper acute stroke
services, continuing variation is likely to reflect
differences in clinical decision-making, in particular the
influence of ambiguous areas within the guidelines,
licensing criteria and research evidence. Clinicians’
perceptions about thrombolysis may now exert a greater
influence on treatment rates than structural/service
factors. This research seeks to elucidate factors
influencing thrombolysis decision-making by using
patient vignettes to identify (1) patient-related and
clinician-related factors that may help to explain variation
in treatment and (2) associated trade-offs in decision-
making based on the interplay of critical factors.
Methods/analysis: A discrete choice experiment (DCE)
will be conducted to better understand how clinicians
make decisions about whether or not to offer
thrombolysis to patients with acute ischaemic stroke. To
inform the design, exploratory work will be undertaken to
ensure that (1) all potentially influential factors are
considered for inclusion; and (2) to gain insights into the
‘grey areas’ of patient factors. A fractional factorial design
will be used to combine levels of patient factors in
vignettes, which will be presented to clinicians to allow
estimation of the variable effects on decisions to offer
thrombolysis.
Ethics and dissemination: Ethical approval for this
study was obtained from the Newcastle University
Research Ethics Committee. The results will be
disseminated in peer review publications and at national
conferences. Findings will be translated into continuing
professional development activities and will support
implementation of a computerised decision aid for
thrombolysis (COMPASS) in acute stroke care.
INTRODUCTION
Stroke is a leading cause of death and dis-
ability; there are approximately 152 000
strokes in the UK every year and between
80% and 85% of these are ischaemic
strokes.1 Intravenous thrombolysis with
recombinant tissue plasminogen activator,
administered within a maximal time window
of 4.5 since onset of symptoms, is the only
effective emergency medical treatment avail-
able for acute ischaemic stroke,2 3 and has
been recommended by the National Institute
for Health and Care Excellence (NICE)
since 2007.4 Despite the considerable evi-
dence for its efficacy in well-defined patient
Strengths and limitations of this study
▪ A key strength of this study is that it is the first
to use a discrete choice experiment (DCE) to
examine clinical decision-making regarding
thrombolysis for patients with acute ischaemic
stroke.
▪ The patient vignette approach will offer enhanced
clinical realism and will facilitate an examination
of the trade-offs that are considered between dif-
ferent patient factors (and levels) when clinicians
are making decisions about thrombolytic
treatment.
▪ It is not possible to include in the DCE every
possible patient factor that may contribute to
variations in decision-making. A structured
mixed methods approach must be employed to
select patient factors (and levels) that are likely
to be contributing most to variation in clinical
decision-making about thrombolysis.
▪ Sampling will be restricted to UK-based clini-
cians, although the results of the DCE may have
relevance to the clinical management of acute
stroke in other countries.
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groups, the Sentinel Stroke National Audit Programme
(SSNAP) estimated that although approximately 14.3%
of patients were eligible to receive thrombolysis between
January and June 2013, only 11.8% received it.5 6
Furthermore, data from the Stroke Improvement
National Audit Programme in 2012 (SINAP) reported
wide variation in thrombolytic treatment rates, even
between neighbouring services.7
Structural factors, such as urgent access to brain CT
scanning, initially accounted for much of the variation
in thrombolytic treatment rates between centres in the
UK; however, with the widespread implementation of
24/7 hyper acute stroke services, continuing variation
may reflect differences in clinical decision-making,
which is influenced by ambiguous or ‘grey’ areas within
the guidelines, licensing criteria and individual-level
interpretation of available research evidence for the effi-
cacy of thrombolysis in the treatment of acute stroke.8 As
a result, clinicians’ decision-making about thrombolysis
is likely to be a greater influence on thrombolysis activity
and variation in treatment rates than structural service
variations.9 Factors that might explain variation in clin-
ical decision-making about thrombolysis include the per-
ceived balance between the probability of benefit of
treatment and the risk of harm due to intracranial
haemorrhage.10 However, it remains unclear as to what
patient and/or clinician-related factors influence the
clinical decision to offer thrombolysis to patients, and
especially their relative contributions to observed vari-
ation in treatment rates. We aim to identify the factors
that contribute to variation in, and influence, clinicians’
decision-making about intravenous thrombolysis for
patients with acute ischaemic stroke and also to investi-
gate the trade-offs made between different patient-
related factors and levels.
The variation between expert clinicians in clinical decision-
making about thrombolysis is reflected in an international
Delphi study, which sought to establish consensus on the rela-
tive contraindications for offering intravenous thrombolysis
in acute ischaemic stroke.8 Although agreement was reached
on 12 of the 18 patient factors, there was a failure to reach
consensus on factors such as age, stroke onset time to treat-
ment, recent medical procedures, spontaneous improvement
rate and blood pressure treatment.8 Licensing criteria cur-
rently restricts treatment to patients aged 80 years or below,
but most clinicians now treat patients over 80 years on the
basis of registry analyses of patients treated in routine prac-
tice, recent randomised trial evidence from The Third
International Stroke Trial (IST-3)3 and increased recognition
of the distinction between chronological and physiological
age. The European Cooperative Acute Stroke Study III
(ECASS III )11 trial supported extension of the time window
for treatment from 3 to 4.5 h and the European license time
window was extended.12 According to the Safe
Implementation of Thrombolysis in Stroke-Monitoring
(SITS-MOST) study, it is common for patients outside the
licensing criteria to be treated,13 suggesting that different
clinicians are satisfied with different levels of evidence and/
or vary in their decision-making process regarding patient eli-
gibility given the same evidence.
Physician-related and patient-related medical and non-
medical factors can also impact on medical decision-
making.14–16 Influences on the consideration of thromb-
olysis have been postulated, and include factors such as
concern about adverse effects, especially symptomatic
intracranial haemorrhage, and uncertainty about effective-
ness.9 17 As others have observed, “managing uncertainty
is central to clinical practice and requires the linking of
experience and evidence: this places specialists at an
advantage” (ref. 18, p.139). It is important, therefore, to
understand how clinician-centred factors such as level of
expertise, age, seniority, practice setting and attitude to
risk can influence the decision to offer thrombolysis.19
The situation is further complicated by the absence of
data on outcomes as a function of individual patient
characteristics, lack of quality decision support tools20 and
lack of consensus on relative contraindications.8
Additional patient factors, such as prior cognitive function,
prior functional ability and comorbidities are also likely to
influence decision-making.14 Nevertheless, little is known
about the relative importance of these medical and non-
medical factors and indeed whether or not other patient-
related medical and non-medical factors, including
clinician-related factors, are at play. Furthermore, some of
these factors are likely to reflect clinical criteria, whereas
others are interpretations of criteria and evidence which is
amenable to education/behaviour change or better pres-
entation of evidence for under and overtreatment.
Aims
The study aims to identify the factors that contribute to
variation in, and influence, clinicians’ decision-making
regarding the use of thrombolysis for treatment of
patients with acute ischaemic stroke. Specifically, the
objectives of the project are:
1. To determine which patient factors influence clinical
decision-making about the offer of thrombolysis;
2. To identify and quantify the trade-offs between
patient factors/levels that clinicians make regarding
the decision to offer thrombolysis and variation in
this decision;
3. To determine which clinician-related factors influ-
ence clinical decision-making about the offer of
thrombolysis (eg, clinician experience, clinical spe-
cialty and attitude to risk);
4. To influence clinicians’ behaviour by translating
learning into continuing professional development
(CPD) activity, national clinical guidelines, support-
ing implementation of an existing thrombolysis deci-
sion support tool and informing clinical audit and
evaluation programmes (SSNAP).
METHODS AND ANALYSIS
To examine the factors that influence clinicians’
decision-making when considering thrombolysis, it is
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important to understand their thought processes when
they are making these decisions in a way that reflects
decision-making in practice. An online discrete choice
experiment (DCE) utilising hypothetical patient vign-
ettes will be conducted to better understand how clini-
cians make decisions about whether or not to offer
thrombolysis, and to capture the underpinning trade-
offs made in decision-making. To inform the final
design of the patient vignettes and clinician-related
factors for inclusion in the DCE, exploratory work will
be undertaken to ensure, insofar as is possible, that all
potentially relevant factors are identified for inclusion in
the study. This exploratory work will adopt a mixed
methods approach to facilitate optimal design of the
DCE. Figure 1 presents an overview of the processes
involved.
Rationale for a DCE to examine clinical decision-making
about thrombolysis
The DCE approach offers a means to examine the
nuances of decision-making, by providing insights into
the (sometimes implicit) trade-offs made between differ-
ent factors and levels, which are not easily captured
through other more traditional research methods. Based
on the tenets of random utility theory,21 a DCE is
designed to elicit participants’ preferences and the rela-
tive importance of different factors/levels within a
decision-making model.22 DCEs assume that there is
more than one factor influencing decision-making and
that all choices involve trade-offs.23 Ryan et al (ref. 23,
p.15) observe that, since “researchers cannot get inside
the heads of these individuals (clinicians) and observe
all factors affecting preferences,” a DCE offers a means
to explore and quantify the implicit trade-offs made
between multiple competing factors within a decision-
making scenario. This method can be used to systematic-
ally assess preferences within any given decision-making
scenario and thereby can be used to access the under-
pinning cognitions of clinicians which lead to a decision
about the offer of thrombolysis. DCEs are widely used in
the health sector,24 including decision-making in areas
such as clinical recommendation of contraceptive type25
and investigating participant preferences for preventative
asthma medication.26 While DCEs have been under-
taken in the field of stroke medicine (eg, to explore
patient preferences for early rehabilitation manage-
ment),27 none have examined the factors that influence
clinicians’ decisions to offer thrombolysis to acute
ischaemic stroke patients.
Clinicians involved in thrombolysis decision-making
will be presented with hypothetical patient vignettes
which vary in terms of their characteristics (patient
factors, eg, age) and the magnitude of these character-
istics (levels, eg, patient age 75 or 85 years) and asked to
state whether they would offer thrombolysis.22 The rela-
tive importance of different patient factors (and levels)
to the decision can then be quantified, and the esti-
mated choice model then used to predict the probability
of offering thrombolysis given certain characteristics of
the patient.22 28 This will enable insight into the patient
factors and levels which influence the decision to offer
thrombolysis. An example of a draft patient vignette is
provided in figure 2. The DCE will also examine
observed variation in decision-making by clinician
factors such as age, experience, clinical background and
attitude to risk (using a six-item version of the Jackson
Personality Inventory Risk-taking subscale).19 29
Exploratory work to establish factors and levels that
potentially influence clinical decision-making about
thrombolysis
In-depth exploratory work, usually involving qualitative
methods and literature review, is an important first stage
in any DCE to establish the factors (characteristics of the
decision-making model) and levels (magnitude of those
characteristics) for inclusion.30 This research will draw
on previously completed work by the project team for
the Developing and Assessing Services for Hyperacute
(DASH) Stroke NIHR-funded programme grant for
applied research.31 This research explored optimal
organisation of prehospital and acute stroke care and
aimed to improve outcomes for stroke patients by build-
ing on the evidence base for future health service inter-
ventions. The programme examined barriers to acute
stroke patient admission, the views of clinicians, the
public, stroke patients and their relatives/carers about
the risks and benefits of thrombolysis and how to
engage patients and their families in decision-
making.32 33 In the current study, we will re-examine
qualitative interview data on the views and experiences
of stroke clinicians about thrombolysis decision-making,
as well as ethnographic data collected through partici-
pant observation and data from the usability testing of a
COMPuterised decision Aid for Stroke thrombolySis
(COMPASS) to ensure that potentially relevant patient
and clinician factors in thrombolysis decision-making
are considered.32 33 In addition, semistructured
one-on-one interviews will be conducted with up to 10
additional stroke clinicians who were not involved with
the DASH study but are based in centres outside the
North East of England. Interviews will be audiorecorded
and transcribed verbatim. The sampling strategy will be
purposive, to include clinicians from the local cardiovas-
cular network and beyond, and will seek to include clini-
cians from hospitals in the upper and lower quartiles of
thrombolysis rates, based on figures from national audit
reports.5–7
Participants will be asked to reflect on their clinical
experience where thrombolysis was considered; in par-
ticular, they will be asked to talk through the typical
decision-making process and then asked to recall grey,
borderline and/or difficult cases, including trade-offs
made and perceived influential factors on their decision.
Additional prompts will include: influential factors
beyond guidelines and licensing criteria; experiences of
adverse events; communicating risks and benefits of
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thrombolysis; attitude to risk; colleagues’ views and
experiences; and approaches and norms within their
practice setting. Anonymised transcripts will be imported
into QSR International’s NVivo 9 to facilitate the coding
and analysis of data.34 The resulting data set will be
coded thematically and analysed using a framework
approach to establish the range of factors (and levels)
that could be included in the DCE.35 In short, these
interviews will be used to identify any additional patient-
related and clinician-related factors that might influence
decision-making that are not accounted for in the exist-
ing qualitative data set from the DASH research pro-
gramme or in the published literature.
The exploratory phase will enable the generation of a
comprehensive list of patient-related and clinician-
related factors that potentially influence decision-making
about whether or not to offer thrombolysis to patients
with acute ischaemic stroke. This list will then be used to
inform the design of a structured prioritisation exercise
(SPE). The SPE will include patient-related factors (and
levels or magnitudes of these factors) that will assist us
in selecting the most influential factors on clinical
decision-making, and also facilitate the elucidation of
where ‘grey’ areas (ie, areas of uncertainty) exist in
decision-making about thrombolysis. Questions within
the SPE will be designed to assist in determining (and
Figure 1 Overview of the
discrete choice experiment
development process.
Figure 2 Example of a draft
vignette.
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operationalising) the relative importance of patient-
related factors (and levels) for decision-making about
thrombolysis, as well as providing insight into the nature
of ‘grey’ areas that exist for each patient factor. The first
phase of the SPE will be hosted online and will be circu-
lated to up to 30 stroke clinicians responsible for
thrombolysis decision-making. The results of the SPE
will be examined using frequency analysis to inform dis-
cussions with an expert panel in the second phase (con-
sisting of three stroke physicians, a trainee stroke
physician, two stroke patient representatives, two health
psychologists, two health economists and a specialist in
epidemiology, public health and decision-making) to
determine which patient-related factors and levels will
be included in the patient vignettes. This panel will also
deliberate on the most relevant clinical information to
be presented in the patient vignettes to ensure that they
are representative of a real-world patient assessment and
provide sufficient information to allow clinicians to
reach a decision about whether or not to offer thromb-
olysis to patients with acute ischaemic stroke.
Experimental design of DCE
A fractional factorial design will be used to combine
patient-related factors and levels to construct hypothetical
patient vignettes. The number of factors and levels will be
identified from initial exploratory work. The narrative
format of vignettes, rather than the traditional tabular
lists of factors and levels, will be used to increase partici-
pant engagement by providing clinical face validity.36
After presentation of each vignette, participants will be
asked whether they would offer thrombolytic treatment
or not (see figure 2 for an example). To further enhance
clinical validity, all scenarios will be discussed with stroke
clinicians in the project management group to ensure
that they are plausible and clinically appropriate and
provide an adequate range and variety of cases. To
further enhance external validity (and allow comparison
of model predictions to actual cases), a subsection of
vignettes will be based, as closely as possible, on real cases
identified through SITS-UK (thrombolysed cases only),37
and a database of anonymised cases (treated and non-
treated) collected as part of a local audit.
Vignettes will also include CT imaging scans/descrip-
tions of CT scans to make the decision-making process
as realistic as possible and to mirror actual clinical situa-
tions. However, to remove subjectivity around the inter-
pretation of CT imaging, a brief description of the
accompanying CT scan findings will also be provided.
Importantly, the experimental design will allow us to
include a number of vignettes that show variation in
patient factors that are likely to be most sensitive to dif-
fering decisions, that is, those difficult ‘grey zone’ cases.
The vignettes will be reduced to a manageable number
using experimental design techniques (fractional factor-
ial design) and incorporated into an online survey.
Within the survey, the case vignettes will be followed by a
series of questions on clinician factors to be used in the
estimation of choice models as covariates such as clin-
ician age, grade/seniority, experience with thrombolysis
and personality type/risk aversion (using the Jackson
Personality Inventory Risk-taking subscale).19 29
The DCE will be programmed into an online survey to
enhance the ease and speed of survey dissemination and
data collection. The survey will be pretested, with a con-
venience sample of up to eight clinicians, to establish
the clinical validity of the vignettes, examine partici-
pants’ understanding and check how long the survey
takes to complete. Pretesting will include a think-aloud
approach,38 using a subset of vignettes, to facilitate adap-
tation of the vignettes and survey instrument. This will
address practical issues, such as length of the survey to
avoid response fatigue,21 28 optimal presentation of
choice sets (vignettes) and views on how to make the
online survey easier to use.28 The vignettes will be
designed to mimic as closely as possible the decision of
interest. This will be in the form of a binary response
(decision to offer thrombolysis or not) as this reflects
routine clinical practice whereby clinicians are faced
with one patient at a time and must decide whether or
not to offer thrombolysis. Clinicians tend to be familiar,
and are likely to be more comfortable, with vignettes as
they are regularly used in training and CPD.
Consequently, participating clinicians may treat the DCE
as a test and thus behave differently to how they would
in the real world. As such, the information sheet preced-
ing the DCE survey will clearly communicate that all
responses will be confidential and individuals will not be
judged on their responses against guidelines/licensing
criteria for thrombolysis.
Participant sampling and recruitment
Optimal sample size requirements for DCEs depend on
knowledge of the true choice probabilities, which are
not known prior to undertaking the research.39 The
final sample size required will also depend on the ultim-
ate design of the DCE, that is, the number of patient
factors included and the number of levels of each factor,
including consideration of the response rate from the
target population. Previous DCE studies have shown that
robust choice models can be estimated from sample
sizes between 50 and 100 respondents.26 39
Clinicians will be recruited via the British Association
of Stroke Physicians (BASP)40 with reminders issued at 2
and 4 months to maximise the response rate. An invita-
tion to participate, together with an information sheet,
will be distributed to members of BASP with a link to
the online DCE survey. In some cases, emergency
department physicians and neurologists may have inde-
pendent responsibility for decision-making about
thrombolysis. Therefore, to take account of the diversity
in service configuration, an invitation to participate will
also be circulated nationally via stroke research network
regional leads and via the Society for Acute Medicine.
Eligibility for participation in the survey will be defined
as the potential participant having independent
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responsibility for decision-making about thrombolysis.
Physicians involved only in discussions about the offer of
thrombolysis will be excluded. To ensure that these cri-
teria are adhered to, a question about the respondent’s
role in decision-making about thrombolysis will be
included in the introductory screening questions.
Analytical plan
The data will be modelled in a random utility theory
framework using limited dependent variable multiple
logistic (hierarchical) regression modelling, in particular
using binary logit models and extensions of such
models. The decision to offer thrombolysis will be mod-
elled as a function of the patient factors/levels described
in the vignettes and the characteristics of the decision-
makers (clinician factors). This will allow investigation of
which patient factors (and levels) drive or inhibit the
clinical decision to offer thrombolysis, as well as which
characteristics of the decision-makers (eg, age, experi-
ence of offering thrombolysis, attitudes to risk) influ-
ence the clinical decision to offer thrombolysis
(observed heterogeneity). Interaction of such clinician
characteristics with patient factors will allow exploration
of how the importance of patient factors/levels may vary
by clinician characteristic (eg, specialty, level of expert-
ise, degree of experience, etc). Unobserved heterogen-
eity will be explored using random coefficients and
scale-adjusted latent class modelling. Using the pre-
ferred model (based on goodness of fit criteria),23 mar-
ginal rates of substitution will be calculated to quantify
the rate at which clinician respondents are prepared to
trade off one patient factor for another, which also
allows investigation of the relative importance, or
ranking, of the characteristics of patients to the decision
to offer thrombolysis.30 41 Predicted probability analysis
will not only investigate the probability of offering
thrombolysis using clinically relevant values on the levels
of factors but will also be used in the exploration of
external validity.
ETHICS AND DISSEMINATION
Interview participants will be informed that any personal
details will be removed from interview transcripts and
will not be disclosed in any reports or publications. As
the DCE will be conducted via an online survey, it will
not be possible to collect signed consent forms from par-
ticipants. Instead, the opening page of the online survey
will clearly state that participation is voluntary and there
is a right to withdraw participation at any stage, without
reason. Participants will be advised that answers will be
confidential. They will then be given a brief description
of the study (with contact details of the lead researcher
should they have any questions) and asked to indicate
their consent to participate by ticking a box and con-
tinuing through the online survey.
The DCE will be used to establish:(1) which patient
factors/levels described in the vignettes are taken
account of by clinicians when deciding to offer thromb-
olysis; (2) which of these factors act as drivers to, or have
a positive impact on, the decision to offer thrombolysis,
and which act as inhibitors, or reduce the likelihood of
offering thrombolysis and (3) how these influence the
appropriate use of thrombolysis. The influence of
characteristics of the clinical decision-makers on such
decisions will also be explored.
These data will be used to increase appropriate use of
thrombolysis for patient benefit by influencing clini-
cians’ knowledge, skills and behaviour via four routes.
▸ The findings will be incorporated into postgraduate
training and continuing professional development
activities relevant to thrombolysis in acute stroke care.
This will be undertaken through the development,
revision and sharing of training materials with the
National Health Service (NHS) Improving Quality
Programme, so that training for stroke physicians and
teams can incorporate the study findings.40 42–44
Results will also be presented at the UK Stroke Forum
and British Association of Stroke Physicians annual
trainees’ event.
▸ The findings will also be used to support implementa-
tion of decision support by building on the outputs of
the previous DASH work, which included the develop-
ment of a computerised decision aid for thrombolysis
—COMPASS.45 The results will enable the develop-
ment of tutorial information to be embedded within
COMPASS, with the aim of optimising its use as a clin-
ical training aid. Information on factors known to drive
or inhibit clinicians’ decisions to offer thrombolysis will
be included within the tutorial to optimise use.
Providing additional information and decision support
to clinicians will lead to better support for risk commu-
nication, consent and decision-making about thromb-
olysis with patients/relatives.
▸ The study outputs will be linked to national clinical
audit (SSNAP). Through this mechanism, it is pos-
sible that the study findings can be used to determine
whether additional data items (eg, use of decision
support tools such as COMPASS) should be routinely
collected about thrombolysis at a national level, and
they will also help in the interpretation of the find-
ings of the national audit.
▸ Finally, the results will be disseminated as national
conference presentations, peer reviewed papers and
reports to the Stroke Research Network, the Stroke
Association and the Intercollegiate Stroke Working
Party to be considered for inclusion in National
Clinical Guidelines.
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